[Lyme borreliosis--guidelines of treatment and expectations of patients].
Clinical and patophysiological aspects of Lyme borreliosis influencing effectives of treatments are introduced. European recommendations--results of EUCALB export group (regarding European multistrains specificity), AAN-American Academy Neurology as well ILADS Working Group based on experience from North America supported of some important studies connected with duration of therapy are described. Expectations of patients are introduced.
Klinika Chorób Zakaźnych i Neuroinfekcji, Uniwersytet Medyczny w Białymstoku.
Joanna
J
Zajkowska
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000906:Antibodies / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D025065:Borrelia burgdorferi / Q000302:isolation & purification; D003955:Diagnostic Tests, Routine / Q000379:methods / Q000592:standards*; D005060:Europe; D006287:Health Planning Guidelines; D006801:Humans; D017053:Infection Control / Q000379:methods / Q000592:standards*; D020852:Lyme Neuroborreliosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D011044:Poland; D017410:Practice Guidelines as Topic / Q000592:standards*; D012955:Societies, Medical / Q000592:standards; D014481:United States
D000900:Anti-Bacterial Agents; D000906:Antibodies; D015415:Biomarkers